Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023
A Phase 1, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PRA023 in Healthy Caucasian and Japanese Adult Volunteers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Cypress, California, United States, 90630
- Altasciences Clinical LA, Inc.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Subjects are required to meet the following criteria in order to be included in the study:
- Japanese subjects must have both natural (not adopted) parents and four grandparents of Japanese origin.
- Caucasian subjects must be of European or Latin American descent (i.e., White).
- Male or female (of non-childbearing potential only) between minimum adult legal age (according to local laws for signing the informed consent document) and 55 years of age.
Females must be of non-childbearing potential and must have undergone one of the following sterilization procedures, and have official documentation, at least 6 months prior to the first dose:
- hysteroscopic sterilization;
- bilateral tubal ligation or bilateral salpingectomy;
- hysterectomy;
- bilateral oophorectomy, or;
- be postmenopausal with amenorrhea for at least 1 year prior to the first dose and have FSH serum levels consistent with postmenopausal status as per Investigator judgment.
- Male subjects must use reliable forms of contraception during sexual intercourse with female partners from screening to 30 days after the end of dosing.
- Good general health as determined by medical history, and by results of physical examination, chest x-ray, vital signs, ECG, and clinical laboratory tests obtained within 28 days (4 weeks) prior to study drug administration.
Exclusion Criteria:
Subjects with the following characteristics will be excluded from the study:
- History or presence of any clinically significant organ system disease that could interfere with the objectives of the study or the safety of the subjects.
- Blood pressure and heart rate are outside the ranges 90-140 mmHg systolic, 60-90mmHg diastolic, heart rate 60-100 beats/min.
- 12-lead ECG with any abnormality judged by the Investigator to be clinically significant, QRS >= 120 milliseconds (msec), or QTcF interval of > 450 msec for men or > 470msec for women.
- Presence or history of any abnormality or illness, which in the opinion of the Investigator may affect absorption, distribution, metabolism or elimination of the study drug.
- Any screening laboratory evaluation outside the laboratory reference range that is judged by the Investigator to be clinically significant.
- History of or current active tuberculosis (TB) infection; history of latent TB that has not been fully treated or current latent TB infection as indicated by a positive QuantiFERON-TB test.
- History of significant allergy to any medication as judged by the Investigator.
- History of alcohol or drug abuse within the past 24 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: PRA023 SC/Placebo IV
Participants randomized to receive active subcutaneous injection/placebo intravenous infusion
|
Drug
Placebo
|
|
Active Comparator: Placebo SC/PRA023 IV Low Dose
Participants randomized to receive placebo subcutaneous injection/active intravenous infusion
|
Drug
Placebo
|
|
Placebo Comparator: Placebo SC/Placebo IV
Participants randomized to receive placebo subcutaneous injection/placebo intravenous infusion
|
Placebo
Placebo
|
|
Experimental: Placebo SC/PRA023 IV High Dose
|
Placebo
Drug
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence, severity, causal relationship of treatment emergent adverse events
Time Frame: Up to 14 Weeks
|
Up to 14 Weeks
|
|
|
F% in Caucasian subjects
Time Frame: Up to 10 Weeks
|
Mean SC versus IV AUC(inf) values
|
Up to 10 Weeks
|
|
Cmax in Japanese subjects
Time Frame: Up to 14 Weeks
|
Maximum concentration after single dose
|
Up to 14 Weeks
|
|
Tmax in Japanese subjects
Time Frame: Up to 14 Weeks
|
Time to reach maximum concentration after single dose
|
Up to 14 Weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cmax in Caucasian subjects
Time Frame: Up to 10 Weeks
|
Maximum concentration after single dose
|
Up to 10 Weeks
|
|
Tmax in Caucasian subjects
Time Frame: Up to 10 Weeks
|
Time to reach maximum concentration after single dose
|
Up to 10 Weeks
|
|
Immunogenicity rate
Time Frame: Up to 14 Weeks
|
Up to 14 Weeks
|
|
|
Change in sTL1A levels
Time Frame: Up to 14 Weeks
|
Up to 14 Weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Prometheus Biosciences, Clinicaltrials Call Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- PR200-105
- 7240-004 (Other Identifier: Merck)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.